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Background: The difficulty in establishing a timely correct diagnosis is a relevant matter of concern for several rare
diseases. Many rare-disease-affected patients suffer from considerable diagnostic delay, mainly due to their poor
knowledge among healthcare professionals, insufficient disease awareness among patients’ families, and lack of
promptly available diagnostic tools. Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal-dominantly
inherited vascular dysplasia, affecting 1:5,000-10,000 patients. HHT is characterized by high variability of clinical
manifestations, which show remarkable overlapping with several common diseases.
Aim: To perform a detailed analysis concerning the diagnostic time lag occurring in patients with HHT, defined as
the time period spanning from the first clinical manifestation to the attainment of a definite, correct diagnosis.
Methods: A questionnaire was administered to the HHT patients previously recruited from 2000 and 2009. Clinical
onset, first referral to a physician for disease manifestations, and first correct diagnosis of definite HHT were
collected. Eventual misdiagnosis at first referral and serious complications occurring throughout the time elapsing
between disease onset and definite diagnosis were also addressed.
Results: In the 233 respondents, the clinical onset of disease occurred at an age of 14.1 yrs, while the age of first
referral and the age of first definite diagnosis of HHT were 29.2 yrs and 40.1 yrs, respectively. Only 88/233 patients
received a correct diagnosis at first counseling. Thus, the diagnostic time lag, represented by the time elapsing
from disease onset and first definite diagnosis of HHT, proved to be 25.7 yrs. Twenty-two patients suffered from
severe complications during this time interval. The diagnostic delay was significantly longer (p< 0.001) in index
patients (first patients who attained definite HHT diagnosis in a given family) than in non-index patients (relative of
index patients). The diagnostic time lag was also significantly associated with education grade (p< 0.001).
Conclusions: Our data report for the first time a systematic inquiry of diagnostic delay in HHT showing that
patients receive a definite diagnosis only after nearly three decades from disease onset. Concerted efforts are still to
be made to increase awareness of this disease among both families and physicians.
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Hereditary Haemorrhagic Telangiectasia (HHT), also
known as Rendu-Osler-Weber Syndrome, is a rare
dominantly-inherited disorder with an estimated preva-
lence of 1:5,000-10,000, characterized by the presence of
epistaxis, mucocutaneous telangiectases, and visceral
arterio-venous malformations (AVMs) in the liver, lung,
brain and GI tract [1,2]. Age-related penetrance and
variable phenotypic expression are commonly found in
HHT patients. Thus far, mutations in two genes have
been found to be responsible for HHT, namely ENG
gene for HHT1 and ACVRL1 gene for HHT2 [3,4].
Several studies have reported that this disease is usu-
ally evidenced by spontaneous episodes of epistaxis in
childhood or adolescence; however, as epistaxis is a com-
mon symptom in the general population, especially dur-
ing childhood, and is shared with several other diseases,
it might easily go unnoticed, rather than recognized as
an HHT-related manifestation [5-7]. In many cases, the
correct correlation between the first HHT-related mani-
festations and a definite diagnosis of HHT is not estab-
lished until other disease features become clinically
overt in adulthood, including vascular complications po-
tentially occurring during this time lag. As a conse-
quence, underdiagnosis of HHT patients is a widespread
phenomenon; in fact, current figures indicate that up to
90 % of HHT patients in United States still lack a defin-
ite diagnosis and proper surveillance [7]. This delay is
most likely due to its rarity and to the lack of knowledge
concerning the disease on the part of physicians. Hence,
the delay in proper diagnosis of HHT merits a more
profound examination.
Several studies have explored the length of time
required for diagnosis of rare diseases [8-12]. Indeed, the
long pathway, often necessary to find the correct diagno-
sis or treatment, typically determines considerable dis-
comfort on the part of the patients involved with rare
diseases, such as HHT, and their families. To our know-
ledge, there are no previous studies focusing on HHT
diagnosis in particular. Therefore, the aim of this study
was to investigate the length of time between symptom




A questionnaire was submitted to the HHT patients
referring to our HHT Interdepartmental Centre at the
University of Bari from 2000 to 2009. The patients
were recruited in alphabetic order from our patient
database with no selection-based criteria and were
considered suitable for the study if they had a definite
HHT diagnosis confirmed by either positive genetic
testing after identification of the familial causativemutation [13], or presence of at least 3 of 4 Curaçao
criteria for HHT clinical diagnosis (epistaxis, mucocu-
taneous telangiectases, familiarity, AVMs in internal
organs [14]) when mutational screening had been in-
conclusive or still ongoing. All recruited patients had
previously attended our Centre and had been subjected
to our complete instrumental screening protocol for
HHT management as well as mutational screening of
ENG and ACVRL1 genes [15]. Henceforth, patients
carrying a mutation in ENG gene will be referred to as
HHT1, patients carrying a mutation in ACVRL1 gene as
HHT2, while patients with unidentified mutation as
HHT?. For each patient enrolled, presence of epistaxis,
mucocutaneous telangiectases, pulmonary arterio-venous
malformations (PAVMs), cerebral arterio-venous malfor-
mations (CAVMs), hepatic arterio-venous malformations
(HAVMs), GI bleeding, and occurrence of HHT-related
complications was retrieved from patient clinical charts
collected during hospitalization in our Centre at time of
instrumental screening. This study was approved by the
ethical committee of the Bari University Hospital.
Questionnaire
Questionnaires were proposed and administered by
means of a telephone interview by one medical doctor
with at least a 5-yr training in HHT (P. P). As a first step,
patients were asked to provide their explicit consent to
participate to the study and only patients who gave their
consent were enrolled in the subsequent interview. The
questionnaire conceived by our study group was struc-
tured with questions aimed to emphasize the exact tim-
ing steps required by the diagnostic process for HHT.
The first part of the questionnaire dealt with demo-
graphics, familial presence of confirmed HHT, in
addition to age of onset and type of first clinical mani-
festation of the disease. Educational background was
classified as follows: a low educational grade (0–7 years),
intermediate educational grade (8–12 years), and high
educational grade (high school diploma or university de-
gree, >12 education years). Patients were split into two
subgroups: “index cases” and “non-index cases”. In the
“index cases” group, we included those patients who
were the first to receive a definite HHT diagnosis within
their family, while in the “non-index cases” group, we
included those patients who were definitely diagnosed
with HHT as the result of a previous HHT diagnosis for
another known family relative. Since our HHT Centre
currently recommends genetic testing to the relatives of
the index cases whose causative mutation has been iden-
tified, also to asymptomatic and pauci-symptomatic indi-
viduals, we further performed analysis of non-index
cases according to how they received the definite diag-
nosis: “clinical diagnosis” for those who received the
1st definite diagnosis if positive to at least 3 clinical
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resulted positive to genetic testing of the familial mu-
tation, albeit not matching clinical Curaçao criteria for
certain diagnosis.
The second part contained questions concerning the
first medical referral for HHT-related manifestations
with regard to date, place (emergency room, hospital,
ambulatory, HHT centre) and specialty of the physician
who was consulted for diagnosis. Distinction was made
between a general practitioner/family physician and spe-
cialist, and also between different specialties (Internal
Medicine, Haematology, ENT, Radiology, Gastroenter-
ology). If HHT was not recognized upon first referral,
data were also collected regarding the referral in which a
definite diagnosis of HHT was made for the first time.
Statistical analysis
The referral time lag (RTL) was assessed as the differ-
ence between the age of the patient’s first referral to a










Nr (%) 53 (23%)




Nr (%) 81 (35%)




Nr (%) 112 (48.1%)
Age at Interview, Mean±SD (years) 57.4± 14.1
[Range] [15;81]
CLINICAL DATA Nr (%
Epistaxis 231 (99




GI bleeding 62 (26age of HHT onset, whereas the diagnosis time lag (DTL)
was defined as the difference between the age of first
definite HHT diagnosis and the age of HHT onset. Fur-
thermore, to gain insight into a possible beneficial effect
exerted on diagnosis of non-index cases, by a definite
diagnosis previously formulated to the index case within
the family, we also reported the time lag elapsing be-
tween the date of definite diagnosis of the index cases
and the date of definite diagnosis of each non-index
cases of the same family, defined as “time lag from index
diagnosis” (LFID). The statistical significance of the
reported data was assessed by univariate analysis (Krus-
kal-Wallis test or Mann–Whitney test, when appropri-
ate). To better identify underlying factors, analysis of
DTL was further performed by multivariate regression
analysis. For this purpose, DTL was transformed in a
two-class variable (DTL ≤ 15 yrs and DTL> 15 yrs): a lo-
gistic model was then set up with DTL being considered
as the outcome categorical variable, while age at inter-
view (age≤ 50 yrs and age> 50 yrs), sex, index/non-indextients, according to Sex, Education Level, Affected Gene,
CLINICAL DATA
Males Females
119 (49%) 114 (51%)
52.4± 17.2 49.7 ± 16.6 p=ns
[11;81] [10;84]
Interm High
69 (30%) 111 (47%)
49.9± 16.2 46.4 ± 14.9 P<0.0001
[15;78] [16;75]
HHT2 HHT?
132 (56%) 20 (9%)
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as independent categorical variables. The computations
were performed by the statistical program R [16]. A p-
value <0.05 was considered significant.
Results
Demographics
A total of 269 consecutive HHT patients were subjected
to telephone interviews, 36 of whom were excluded from
subsequent analysis due to either refusal to participate
or incomplete data collection. Therefore, 233 patients
were enrolled in the present study (119 M:114 F). The
mean age at the time of interview of all 233 enrolled
patients was 51.1 years, as the mean age for male vs fe-
male patients was 52.4 yrs and 49.7 yrs, respectively.
The group of “index cases” was composed of 112
patients and the group of “non-index cases” of 121
patients. A causative mutation had been identified in
213 patients, 81/233 HHT1 (34.8 %) and 132/233 HHT2
(56.5 %), while 20/233 patients (9.4 %) had no mutation

















Onset Age, Mean±SD (years) 16.2 ± 13
[Range] [3;60]
CLINICAL ONSET Nr
Epistaxis alone 202 (
Epistaxis and Mucocut. Tel. 15 (
Epistaxis and GI bleeding 2 (
Epist., Mucocut. Tel, and GI bleeding 1 (
Mucocut Tel. (bleeding+non-bleeding) 6 (
GI bleeding 2 (
PAVM-related Accidents 2 (
CAVM-related Accidents 1 (
Asymptomatic (only Genetic testing) 2 (educational level, 69 an intermediate level, and 111 a
high level. Demographic and clinical data of the 233
patients are shown in Table 1.
First manifestation of HHT disease
Among the 233 patients enrolled, 231 had manifested
overt symptoms related to HHT by the time of the inter-
view. The mean age at onset was 14.1 ± 11.2 years [range
3–60]. Data regarding clinical onset are shown in Table 2.
Two adult patients who were first-degree relatives of
definitely affected individuals reported no subjective
manifestations of HHT disease until the date of inter-
view. For these two patients, diagnosis of HHT was
obtained by genetic testing for the previously-identified
familial mutation. A subsequent medical evaluation
noted a few mucocutaneous telangiectases, previously
unrecognized by the patients, while instrumental screen-
ing evidenced silent HAVMs in both subjects and
PAVMs in one of them. An additional three patients
(two of which in paediatric age) had no subjective mani-
festations at the time of diagnosis (which was performeds, according to Sex, Education Level, Affected Gene, and
F HHT
Males Females
14.6± 12.6 13.6± 9.7 p=ns
[3;60] [3;50]
Interm High
12.2± 9.8 13.8± 10.7 p=0.115
[3;60] [3;58]
HHT2 HHT?
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eous epistaxis before the time of the interview.
Epistaxis represented the onset of HHT disease in
220/233 (94.4%) index cases. Epistaxis alone was re-
ported to be the first manifestation in 202/233 (86.7%)
in this group, whereas in 18/233 (7.7%) patients add-
itional manifestations were reported to occur at the
same age as epistaxis onset: appearance of mucocuta-
neous telangiectases was reported by 15 patients, GI
bleeding episodes by 2 patients, while one patient
reported both visible mucocutaneous telangiectases and
overt GI bleeding episodes occurring at the same age as
the first nosebleeds. A cerebrovascular accident occurred
as the onset of disease in 3/233 (1.3%) otherwise asymp-
tomatic individuals: brain abscess secondary to PAVMs
in 2 cases, while seizures secondary to large CAVMs oc-
curred in one case. Onset of non-bleeding mucocuta-
neous telangiectases and appearance of bleeding lip
telangiectases occurred in five patients and in one pa-
tient, respectively. The overall age at first physician
counselling for HHT-related symptoms was 29.2 ± 16.0
years [range 3;75] for all 233 patients, with an RTL of
14.9 ± 14.4 years [range 0;65].First definite diagnosis of HHT
Of the 233 patients included in the present study, a def-
inite diagnosis for HHT was received at the age of
40.1 ± 17.2 years [range 3;78]. Only 88/233 (37.8%)
patients attained the definite diagnosis of HHT at the
first referral. Among the 112 index cases, only 28

















Age at Diagnosis, Mean±SD (years) 45.9 ± 15.3
[Range] [7;78]first counselling. Regarding the remaining 84 patients,
48 (42.8%) received an incorrect diagnosis and 36
(32.2%) did not receive any diagnosis. Among the 121
non-index cases, 60 (49.8%) received a definite diagno-
sis of HHT at first counselling, 41 of which were for-
mulated by HHT Centres. In the remaining 61
patients who did not receive a correct diagnosis of
HHT upon first referral, an incorrect diagnosis was
provided to 36 patients, whereas no diagnosis was for-
mulated for 25 patients. The incorrect diagnoses
included: “fragility of capillary vessels” in 66 cases,
“angiomas” (labial, lingual, hepatic, congenital) in 5
cases, “tumoral mass lesions” in 3 cases, whereas the
following wrong diagnosis were each formulated in 1
case: “hemoptysis from pulmonary angioma”, “multiple
non-syndromic pulmonary arteriovenous fistulas”, “an-
aemia”, “diffuse angiodysplasia”, “bleeding cerebral ab-
scess”, “nasal polyps”, “congenital disorder”, “sinusitis”,
“thrombocytopenia secondary to depression”, “acute
cholecystitis”. Data regarding the 1st definite diagnosis
of HHT in the various subgroups are shown in
Table 3.Diagnostic time lag (DTL)
In the overall group of 233 patients, definite diagnosis of
HHT was obtained after a DTL of 25.7 ± 17.4 years from
the onset of HHT manifestations, with a wide range
both in index and non-index patients (from within one
year to 73 years). Regarding the index cases, only 3/112
(2.7%) patients were diagnosed as having definite HHT
within the first year after the disease onset, and onlycording to Sex, Education Level, Affected Gene, and
GNOSIS OF HHT
Males Females
41.2± 17.6 38.9± 16.8 p=ns
[7;78] [3;73]
Interm High
37.1 ± 16 35.5± 14.5 P<0.0001
[4;71] [7;73]
HHT2 HHT?
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hand, 15/112 (13.3%) index patients had to wait 50 years
or longer to receive a definite HHT diagnosis. In the
non-index subgroup, only 7/121 (5.8%) patients had a
definite HHT diagnosis within the first year after the dis-
ease onset and only 3/121 (2.5%) within the second year
(with five additional patients with positive genetic testing
before HHT onset), while 9/121 (7.4%) patients had to
wait longer than 50 years. In the multivariate analysis,
DTL was significantly correlated with age at interview (p
< 0.0001) and educational level (p< 0.05), and with
index/non-index status (p< 0.05) and educational level
(p< 0.01) after removal of the age from the model. Con-
versely, neither did univariate or multivariate analysis
show any significant difference in DTL between male
and female patients, either before or after removal of the
age from the model (Table 4). No significant difference
was shown by univariate analysis with respect to affected
gene (Table 4). Although the affected gene seemed to be
significantly associated to DTL by multivariate analysis
(p< 0.01), the association was not significant after re-
moval of the age from the model.
Effect of Index/non-index status
The HHT disease arose at the age of 16.2 ± 13 years in
index cases vs 12.1 ± 9.1 years in non-index cases (p-
value <0.001; Figure 1). The age at 1st referral for HHT-
related manifestations was 31.7 ± 15.9 years [range 6;71]



















27.7 ± 16.6 23.4± 17.3 3
[0;68] [0;73]
INDEX/NON-INDEX STATUS Index Non-Index
DTL, Mean±SD (years)
[Range]
29.1 ± 18.0 22.6± 16.7
[0;73] [0;68]
Univariate and multivariate analysis were performed as described in Methods sectio
Multivariate analysis after removal of age.index cases (p< 0.05; Figure 1), respectively. Thus, the
RTL was 14.9 ± 14 years [range 0;64] vs 14.8 ± 14.7 years
[range 0;65] for index cases vs non-index cases, respect-
ively (p = ns). Among the index cases, the first referral
for HHT-related features was to a general practitioner in
8/112 patients (7.1%), an HHT centre in 5/112 patients
(4.4%), an ENT doctor (62.5%) in 70/112 patients, while
29/112 patients referred to other specialists (25.9%).
In the non-index-cases subgroup, the first referral for
HHT-related features was to a general practitioner in
8/121 patients (6.7%), to an HHT Centre in 41/121
patients (33.7%), to an ENT doctor in 43/121 patients
(35.6%), and to another specialist in 29/121 patients
(23.9%). The proportion of patients who referred to an
HHT Centre was significantly different (p< 10-7) be-
tween index and non-index cases. In the index group
the definite diagnosis was obtained at age 45.9 ± 15.3
years, compared to an age of 34.6 ± 17.1 years in the
non-index cases (p< 0.00001, Figure 1). In particular,
the DTL was 29.1 ± 17.8 years in the index cases vs.
22.6 ± 16.7 years in the non-index cases (p-value
<0.001 at univariate analysis; Figure 1). Although in
the initial step of multivariate analysis the DTL did
not seem to be significantly correlated with index/non-
index status, removal of age from the model disclosed a
statistically significant contribution of index/
non-index status to the DTL (p <0.05; Table 4).
When non-index cases were analyzed according to
how they received the definite diagnosis, those withing to Sex, Education Level, Affected Gene, and
E LAG (DTL)
Univariate and Multivariate Analysis
(a) (b) (c)
Females
5.1 ± 15.6 p=ns p=ns p=ns
[0;62]
High
1.4 ± 15.2 P<0.0001 P<0.05 P<0.01
[0;64]
HHT?
3.1 ± 19.6 p=ns P<0.01 p=ns
[2;61]
P<0.01 p=ns P<0.05
n. (a) Univariate analysis, (b) Multivariate analysis before removal of age, (c)
Figure 1 Timing steps of diagnosis according to Index/Non-Index Status. RTL = Referral Time Lag; DTL =Diagnosis Time Lag.
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those with clinical diagnosis (14.4 ± 14.8 years [range
0;65] vs. 27 ± 16.2 years [range 0;68], respectively;
p< 0.001). Similarly, the RTL of non-index cases with
genetic diagnosis was significantly lower (10.9 ± 14.6
years [range 0;65]) than RTL of non-index cases
with clinical diagnosis (16.7 ± 14.9 years [range 0;62];
p< 0.05). When considering the non-index cases, the
diagnostic delay consistently dropped down from a
DTL of 22.6 ± 16.6 years to a value of 6.4 ± 8.4 years
if calculated as LFID (i.e. the difference between date
of diagnosis of the index case and date of diagnosis of
the non-index cases of the same family).
Effect of educational level
The different educational levels proved to be inversely
correlated with the length of DTL; in fact, the diagnostic
delay was reported at its highest value (36.4 ± 18.0 yrs)
in the patients characterized by a low educational grade,
but it was considerably reduced in the patients with
intermediate educational level (24.5 ± 17.2 yrs), and it
improved even more in those with higher educational
levels (21.4 ± 15.2 yrs). As shown in Figure 2, this differ-
ence was statistically significant in both index and non-
index cases (p< 0.01). Multivariate analysis also indi-
cated a significant effect of educational level on DTL(p< 0.05) before and after removal of age at interview
from the model.Clinical complications
A total of 22 patients (12 index and 10 non-index) were
affected by severe life-threatening complications second-
ary to visceral AVMs during the time lag elapsing HHT
onset and the correct definite HHT diagnosis (i.e. the
DTL), as shown in Figure 3. Among the index cases, 12/
112 (10.6%) patients suffered from complications during
DTL, with four patients suffering from more than one
complication (a total number of 18 episodes). Similarly,
in the non-index group, 10/121 (8.3%) patients suffered
from unexpected complications over the DTL period,
with three patients being affected by more than one
complication event, with a total of 13 episodes. Lastly, in
three additional patients (two index and one non-index
cases), severe sudden complications represented the ac-
tual onset of HHT disease (as described in “First mani-
festation of HHT Disease” paragraph). In twenty of the
22 complication-affected patients, life-threatening acci-
dents were secondary to large cerebral, pulmonary, and
colonic AVMs, and would have likely been avoided
by appropriate preventive treatment, whereas in the
remaining two patients complications were secondary
Figure 2 Referral Time Lag (RTL) and Diagnosis Time Lag (DTL) according to Index/Non-Index Status and Grade of Education. For each
subgroup, the mean value of age of onset, age of 1st referral, and age of 1st definite HHT diagnosis are indicated. In X-axis the time before
clinical onset is shown by a white dashed bar. The time comprised between clinical onset and attainment of definite diagnosis of HHT
(corresponding to DTL) is shown by a grey full bar. For each subgroup, the mean age of first referral to a physician is labeled by a black
vertical rod.
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only effective therapeutic option.
Discussion
The astonishing finding arising from this study is the
long duration of the time lag occurring between the
onset of HHT-related manifestations and the formula-
tion of a definite HHT diagnosis, which resulted to
elapse for an average period of almost three decades.
Even though several publications have acknowledged
that misdiagnosis often occurs in HHT disease [3,17,18],
this is the first report of a systematical inquiry of diag-
nostic time delay (DTL) regarding HHT. The difficulty
in obtaining the correct diagnosis proved to represent a
dramatic barrier for most HHT patients. This issue
represents a general matter of concern for the majority
of rare diseases; in fact, this long-lasting search for diag-
nosis entails numerous referrals to various specialists as
well as several instrumental examinations, representing
a time-consuming process which is frequently inconclu-
sive since patients often receive incorrect diagnoses.
Naturally, this frustrating delay considerably affects the
patients’ quality of life, with a subsequent worsening of
their clinical status and marked psychological distress,
for both patients and their families [12].
Furthermore, in the specific case of HHT, a late diag-
nosis delays the beginning of proper treatment. The lack
of a correct HHT diagnosis prevented the patients from
benefiting from safe and effective preventive treatmentfor visceral AVMs carrying marked clinical significance.
In fact, current guidelines for HHT recommend preemp-
tive radiologic survey and treatment for pulmonary
AVMs and outline best practice management for AVMs
and complications in other organs [19]. In our study,
sudden severe complications secondary to visceral
AVMs occurred in 22 patients during the DTL. Since
these vascular accidents are potentially life-threatening
and characterized by considerable disability sequelae,
they often result in need for costly neuromotor support
and/or pharmacological treatments. Hence, the necessity
for a prompt diagnosis of HHT can be also emphasized
not only in terms of improved patients’ quality of life
(which should itself represent the most relevant aim of
health care), but also in terms of economic impact. A
rapid diagnosis of HHT would thus permit to reduce the
financial burden of such permanent aftermath on fam-
ilies and/or health care agencies [20].
Based on our results of this study, there is still an ex-
tensive need to further disseminate knowledge of HHT
among the community of physicians as well as among
relatives of patients with a definite diagnosis of HHT,
thus reducing diagnostic delay and providing optimal
management to as-yet undiagnosed HHT patients. As
the majority of definite HHT diagnoses were formulated
by HHT Centres, the present work stresses the relevance
of the role played by these institutions [21] in providing
a definite diagnosis of HHT within acceptable time lim-
its. Moreover, our results firmly suggest the existence of
Figure 3 (See legend on next page.)
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Figure 3 (Panel A: Index patients; Panel B: Non-index patients). Twenty-two patients suffered from severe complications before
attainment of HHT definite diagnosis. Each horizontal bar represents one given patient - identified by a number on Y-axis - who suffered from
AVM-related complications over the time of Diagnosis Time Lag (DTL). In X-axis the time before clinical onset is shown by a white dashed bar.
The time comprised between clinical onset and attainment of definite diagnosis of HHT (corresponding to DTL) is shown by a grey full bar. For
each patient, the first referral to a physician is labeled by a black vertical rod. Star-shaped markers indicate complication events: BA = Brain
Abscess; BS = Brain Stroke; TIA = Transient Ischemic Attack; ICH= Intracranial Haemorrhage; PRH= Pulmonary Haemorrhage; GRH=Haemorrhage
from Large Gastrointestinal Colonic AVM; SZ= Seizures; HOF=High-Output Heart Failure; LINS = Liver Insufficiency; OLTx =Orthotopic Liver
Transplantation.
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should be made to establish a network involving ENT
specialists and family physicians in the activity of HHT
Centres, based on the observation that most patients,
both index and non-index, initially refer to such medical
professionals when subjected to recurrent nosebleeds.
Reasons underlying the diagnostic delay
The main reason accounting for such a long diagnostic
time lag most likely lies in the insufficient knowledge of
HHT disease by the medical community due to its low
prevalence, similar to that of many other rare diseases.
To gain a better insight into this issue, we decided to
compare the diagnostic lag found for HHT to that previ-
ously reported for other rare diseases. After completion
of this study, a review of current literature for several
rare diseases was performed, including the Eurordiscare
studies [12]. These studies reported that the arc of timeFigure 4 Diagnostic Time Lag (DTL) in several Rare Diseases. In Y-axis,
Mediterranean Fever [9]; A1-ATD=Alfa-1 Antitrypsin Deficiency [10]; RP = Re
MarS =Marfan Syndrome [12]; PWS= Prader-Willi Syndrome [12]; DMD=Du
Disease [12]; TS = Tuberous Sclerosis [12]; EDS = Ehlers-Danlos Syndrome [12
Telangiectasia (this work).required to reach a correct diagnosis largely varies for
the different rare diseases (summarized in Figure 4)
[8-12]. When comparing our results to studies focusing
on diagnostic delay, the DTL for HHT was one of the
longest (25.7 years). Several explanations can be
evoked to account for such a long diagnostic delay. (i)
Firstly, HHT is a highly heterogeneous disorder lacking
a specific clinical hallmark and is characterized by
clinical features which overlap with several unrelated
common diseases, thus obscuring more specific under-
lying signs and leading to misdiagnosis [7,22]. In fact,
it is noteworthy that those diseases with symptoms
mainly unspecific and/or quite overlapping with many
common diseases such as Familial Mediterranean Fever
or Ehlers-Danlos syndrome, proved to be more prone
to misdiagnosis and to have the highest DTLs. On the
contrary, those rare diseases characterized by specific
clinical/instrumental signs, such as the Prader-Willithe DTL is shown for the following rare diseases: FMF= Familial
lapsing Polychondritis [11]; ALS =Amyotrophic Lateral Sclerosis [9];
chenne Muscular Dystrophy [12]; CF = Cystic Fibrosis [12]; CrD=Crohn’s
]; FXS = Fragile-X Syndrome [12]; HHT=Hereditary Haemorrhagic
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shorter DTL than HHT (Figure 4). (ii) Secondly, the
longer DTL for HHT may also be attributable to the
lack of any reliable biochemical test for HHT diagnosis,
whereas such laboratory tests are available for other
disorders [2]. As reported in Figure 4, diagnostic delay
is shorter for those diseases which can currently rely
on effective biochemical/histological tests, such as cys-
tic fibrosis, Alpha-1 anti-trypsin deficiency and Crohn’s
disease. In spite of the studies of several research
groups, no accurate biochemical tests currently exist to
diagnose HHT [23-28]. (iii) A third explanation con-
sists in the intrinsic clinical features of HHT itself,
which tends to have less severe manifestations and a
better clinical evolution than many of the other afore-
mentioned rare diseases. In fact, those diseases with
rapid deterioration of psychomotor abilities, such as
Amyotrophic Lateral Sclerosis, Cystic Fibrosis, and
Duchenne’s Muscular Dystrophy, have a shorter DTL.
On the other hand, diseases involving a low neuromo-
tor impairment, such as Familial Mediterranean Fever,
or those which remain silent for decades and then pre-
cipitate sudden life-threatening events, such as Ehlers-
Danlos Syndrome, have a longer DTL. Clinical features
of HHT are characteristic of this latter disease group.
Factors affecting diagnostic delay
Our study suggests that the DTL in HHT is significantly
associated with two major factors: index/non-index
status and educational level. Our results show that the
index cases, who have no known relatives with a definite
diagnosis of HHT, undergo an even longer diagnostic
delay (29.1 years, represented by 14.9 years of RTL
followed by 14.2 years awaiting for the correct diagnosis).
Interestingly, we noted that non-index patients were
not only properly diagnosed at a younger age than
index patients, but also reported a statistically signifi-
cant earlier clinical onset and earlier age at first refer-
ral. These data suggest that non-index patients have a
considerably greater awareness of their clinical status,
as expected. As a consequence, they were probably
more alerted at the age of their very first epistaxis epi-
sodes (the disease onset for most of them) and were
likely more accurate to record disease onset, since they
were able to recognize it as the same stigmata affecting
one of their ascendants/older siblings (usually represent-
ing the index case). The fact that the non-index cases re-
ceive a definite diagnosis in shorter time also depends to
a second, synergistic factor, involving the physician’s abil-
ity to diagnose HHT more quickly due to the presence of
a known HHT-affected index case in the familial history.
As shown by our study, the attainment of HHT definite
diagnosis in the first member of a family conveys a
marked reduction in diagnostic delay of the index-caserelatives, given that non-index cases receive a definite
diagnosis 6.4 yrs on average after the index-case diagno-
sis, thereby representing a consistent improvement with
respect to the time lag elapsing from their clinical onset
(22.6 yrs). The relationship between index/non-index
status and DTL proved to be statistically significant in
both univariate and multivariate analysis, even though it
failed to reach significance when age at interview was
included in the multivariate analysis. This suggests that
age acts as a confounding factor in the analysis, likely
due to the expected relationship existing between
index/non-index status and older age, being the non-
index cases usually descendants or younger siblings
than their index cases.
It is plausible that the presence of a known certainly
HHT-affected relative in non-index’s familial history
might help the diagnostician in at least three ways: by
heighten knowledge of this disease in the referred phys-
ician, by providing a major criterion for clinical diagno-
sis (since the presence of a certainly affected 1st-degree
relative is one of the four Curaçao criteria for clinical
HHT diagnosis [14]), and by permitting genetic testing
(in that genetic testing can be carried out only when the
disease-causing mutation in either ENG or ACVRL1
gene has been previously identified in an index-case with
certain HHT [6]). The benefit of availability of genetic
testing, very well evidenced by the difference in DTL
among the non-index subgroup (14.4 years vs. 27 years
in genetically-diagnosed vs. clinically-diagnosed, respect-
ively) should prompt Institutions, physicians and
Patients’ Associations to remove as many barriers as
possible to the employment of genetic screening for
early diagnosis, thus far an underused option [29]. The
correlation of DTL with the mutated gene was far less
clear, since univariate analysis found no significant dif-
ference in HHT1 vs. HHT2 patients, and multivariate
analysis showed a correlation which, however, failed to
reach statistical significance after removal of age from
the model. A possible reason underlying the unclear role
of mutated gene in DTL might consist in the prominent
HHT2 composition of our cohort, as commonly
observed in the Mediterranean countries [30], which
might obscure the mutated-gene-contribution to the
DTL.
Regarding the educational level of patients, our results
demonstrated a gradual and significant decrease in DTL
between people with different educational backgrounds.
The relationship between educational level and DTL
proved to be statistically significant in both univariate
and multivariate analysis. The observation that educa-
tion grade is one of the major factors affecting DTL can
be explained by the well-known correlation between
educational attainment and people’s behavior approach
to their health status. Furthermore, subjects with higher
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relationships and have an easier access to informative
sources, such as the web-based tools, providing the ne-
cessary knowledge to reach the goal of a correct
diagnosis.
Beside a high DTL, we also observed a long RTL.
These considerations pinpoint the attention towards the
insufficient knowledge of HHT among society. Owing to
its extreme variability in manifestations, HHT not only
suffers from poor recognition by physicians, but also by
patients themselves. Since epistaxis can be present also
in the general population, at times not related with a
particular disease, nosebleeds may be discounted for
many years as an annoyance within the range of normal-
ity, rather than perceived as the symptom of an under-
lying disease, by many patients/families [31]. This issue
is currently being addressed by the HHT Foundation
International, in order to improve awareness of this dis-
ease among as-yet undiagnosed HHT individuals [32].
Finally, some historical notes are worth of mention
when discussing the long diagnostic delay in HHT, as
well as in many other rare diseases. The time needed to
accomplish a definite correct diagnosis depends on the
complexity of essential diagnostic steps and the cognitive
biases of the physician. A correct diagnosis will be for-
mulated as quickly as the disease in question is retrieved
from the physician’s working memory [33]. Cognitive
biases, leading to misdiagnosis, might be synthesized by
the statement “We recognize what we already know”,
historically attributed to Socrates (Vth Century B.C.).
HHT, or the Rendu-Osler-Weber disorder, is an example
of this phenomenon. Another of such example is Cush-
ing’s syndrome, often characterized by clinical hetero-
geneity and misdiagnosis [33,34]. Notably, the first
typical description of a patient with Cushing’s syndrome
was probably made by Sir William Osler, actually Harvey
Cushing’s mentor [34] and one of the three eponyms of
Rendu-Osler-Weber disorder. However, Osler was un-
able to properly acknowledge the existence of this new
syndrome and formulated an incorrect diagnosis. Thus,
Cushing’s syndrome was shed light onto only 20 years
later, representing a typical instance of diagnostic delay,
which some authors [34] have proposed to name “Osler’s
phenomenon”.Conclusions
Patients with HHT experience a very long diagnostic
delay before definitely attaining the correct diagnosis.
Considerable endeavors are still required to spread
awareness of this disease among health care profes-
sionals and patients’ relatives, in order to reduce the
inacceptably long time lag associated with HHT
diagnosis.Abbreviations
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